ACUTE MEGACARYOBLASTIC LEUKEMIA IN CHILDREN: DIAGNOSTICS AND MRD MONITORING

Objective: Acute megakaryoblastic leukemia (AMKL) is a rare subtype of acute myeloid leukemia (AML) associated with poor prognosis for all patients except children with t(1;22) or Down syndrome. The frequency of complete remission in case of AMKL is comparable to the frequency of it in other variant...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Aleksandra Palladina, Natalya Kupryshina, Nikolai Tupitsyn, Aleksander Popa
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/c8a63216ff294707b239f6e33b9222d9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c8a63216ff294707b239f6e33b9222d9
record_format	dspace
spelling	oai:doaj.org-article:c8a63216ff294707b239f6e33b9222d92021-11-10T04:33:29ZACUTE MEGACARYOBLASTIC LEUKEMIA IN CHILDREN: DIAGNOSTICS AND MRD MONITORING2531-137910.1016/j.htct.2021.10.992https://doaj.org/article/c8a63216ff294707b239f6e33b9222d92021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921011391https://doaj.org/toc/2531-1379Objective: Acute megakaryoblastic leukemia (AMKL) is a rare subtype of acute myeloid leukemia (AML) associated with poor prognosis for all patients except children with t(1;22) or Down syndrome. The frequency of complete remission in case of AMKL is comparable to the frequency of it in other variants of AML but the median survival is much lower. This determines the necessity of more thorough evaluation of treatment effect using flow cytometry accessment of minimal residual disease (MRD). Methodology: The clinical and immunological profile of 8 girls and 9 boys with de novo AMKL between the ages of 3 months–11 years old was analyzed. The primary leucocytosis median was 10,25; only one patient had hyperleukocytosis (53х109/l) at presentation.The measurement of MRD was performed in 6 patients using multiparameter flow cytometry. The measurement of MRD performed after induction therapy on the basis of megakaryocytic markers, weak CD45 expression using the initial iimmunophenotype patterns. Results: Adequate measurement of the level of MRD had required extensive diagnostic immunophenotyping in order to determine the aberration of megakaryoblasts. CD9(83,3%), CD33(75%), CD34(60%), CD13(50%) apart from megakaryocyte markers (100%) were most common for blast cells in case of AMKL. The expression of CD7 antigen was as frequent as of CD117-40%. The MRD level ranged from completely negative (0%; 0.006%) to evident (1.05%). Conclusion: The detection of residual tumor megakaryoblasts in AML M7 using flow cytometry is a promising method for assessing the effect of therapy. Adequate measurement of MRD requires detailed immunophenotyping in the diagnosis to determine the aberrations of megacaryoblasts immunophenotype.Aleksandra PalladinaNatalya KupryshinaNikolai TupitsynAleksander PopaElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S25- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Aleksandra Palladina Natalya Kupryshina Nikolai Tupitsyn Aleksander Popa ACUTE MEGACARYOBLASTIC LEUKEMIA IN CHILDREN: DIAGNOSTICS AND MRD MONITORING
description	Objective: Acute megakaryoblastic leukemia (AMKL) is a rare subtype of acute myeloid leukemia (AML) associated with poor prognosis for all patients except children with t(1;22) or Down syndrome. The frequency of complete remission in case of AMKL is comparable to the frequency of it in other variants of AML but the median survival is much lower. This determines the necessity of more thorough evaluation of treatment effect using flow cytometry accessment of minimal residual disease (MRD). Methodology: The clinical and immunological profile of 8 girls and 9 boys with de novo AMKL between the ages of 3 months–11 years old was analyzed. The primary leucocytosis median was 10,25; only one patient had hyperleukocytosis (53х109/l) at presentation.The measurement of MRD was performed in 6 patients using multiparameter flow cytometry. The measurement of MRD performed after induction therapy on the basis of megakaryocytic markers, weak CD45 expression using the initial iimmunophenotype patterns. Results: Adequate measurement of the level of MRD had required extensive diagnostic immunophenotyping in order to determine the aberration of megakaryoblasts. CD9(83,3%), CD33(75%), CD34(60%), CD13(50%) apart from megakaryocyte markers (100%) were most common for blast cells in case of AMKL. The expression of CD7 antigen was as frequent as of CD117-40%. The MRD level ranged from completely negative (0%; 0.006%) to evident (1.05%). Conclusion: The detection of residual tumor megakaryoblasts in AML M7 using flow cytometry is a promising method for assessing the effect of therapy. Adequate measurement of MRD requires detailed immunophenotyping in the diagnosis to determine the aberrations of megacaryoblasts immunophenotype.
format	article
author	Aleksandra Palladina Natalya Kupryshina Nikolai Tupitsyn Aleksander Popa
author_facet	Aleksandra Palladina Natalya Kupryshina Nikolai Tupitsyn Aleksander Popa
author_sort	Aleksandra Palladina
title	ACUTE MEGACARYOBLASTIC LEUKEMIA IN CHILDREN: DIAGNOSTICS AND MRD MONITORING
title_short	ACUTE MEGACARYOBLASTIC LEUKEMIA IN CHILDREN: DIAGNOSTICS AND MRD MONITORING
title_full	ACUTE MEGACARYOBLASTIC LEUKEMIA IN CHILDREN: DIAGNOSTICS AND MRD MONITORING
title_fullStr	ACUTE MEGACARYOBLASTIC LEUKEMIA IN CHILDREN: DIAGNOSTICS AND MRD MONITORING
title_full_unstemmed	ACUTE MEGACARYOBLASTIC LEUKEMIA IN CHILDREN: DIAGNOSTICS AND MRD MONITORING
title_sort	acute megacaryoblastic leukemia in children: diagnostics and mrd monitoring
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/c8a63216ff294707b239f6e33b9222d9
work_keys_str_mv	AT aleksandrapalladina acutemegacaryoblasticleukemiainchildrendiagnosticsandmrdmonitoring AT natalyakupryshina acutemegacaryoblasticleukemiainchildrendiagnosticsandmrdmonitoring AT nikolaitupitsyn acutemegacaryoblasticleukemiainchildrendiagnosticsandmrdmonitoring AT aleksanderpopa acutemegacaryoblasticleukemiainchildrendiagnosticsandmrdmonitoring
_version_	1718440691735986176

ACUTE MEGACARYOBLASTIC LEUKEMIA IN CHILDREN: DIAGNOSTICS AND MRD MONITORING

Ejemplares similares